Author(s):
Pooja Nandi, Teena Ahuja, Bishal Singh
Email(s):
teenachhabra1509@gmail.com
DOI:
10.52711/2231-5713.2025.00054 
Address:
Pooja Nandi, Teena Ahuja*, Bishal Singh
School of Pharmaceutical Sciences, CT University, Ludhiana - 142024, Punjab, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
Stroke remains a leading cause of disability and death globally, with accumulating evidence suggesting that inflammation plays a key role in its pathogenesis. This review has summarized current evidence regarding prominent inflammatory biomarkers high-sensitivity C-reactive protein (hsCRP), interleukin-6(IL-6), interleukin-18(IL-18), tumor necrosis factor-alpha (TNF-a), and serine proteinase inhibitor A3(SERPINA3) and their involvement in stroke severity, progression, and recurrence. hsCRP was associated with larger infarct volume and predicted cardiovascular events in 8,420 patients. IL-6, detectable within 2.5hours of stroke onset, has been linked with 8% rise in recurrence risk for each 1pg/mL increment. IL-18 was associated with neuroinflammation and post-stroke depression with reduced levels reducing risk of cardioembolic stroke, though its role in acute environment remains uncertain. TNF-a levels dropped from 7.39 to 5.12pg/mL within seven days, in relation to poor functional outcome and enhanced atherosclerotic risk. Elevated levels of SERPINA3 (>78.90ng/mL) have been linked with increased cerebral small vessel disease burden. These biomarkers have been promising for clinical application in risk stratification and pathway-targeting interventions, e.g., IL-6 or TNF-a pathway targeting. There are, however, limitations, including the non-causal role of hsCRP in atherosclerosis, controversial data on IL-18, and lack of standard assays for SERPINA3. This review has emphasized the need for further validation in representative cohorts, the development of composite biomarker panels, and the incorporation of these markers into predictive models to enable enhanced clinical decision-making. In summary, the findings confirm the central role of inflammation in stroke and validate biomarker-guided strategies to optimize patient outcomes.
Cite this article:
Pooja Nandi, Teena Ahuja, Bishal Singh. Inflammatory Biomarkers in Stroke: A Comprehensive Review. Asian Journal of Pharmacy and Technology. 2025; 15(4):370-6. doi: 10.52711/2231-5713.2025.00054
Cite(Electronic):
Pooja Nandi, Teena Ahuja, Bishal Singh. Inflammatory Biomarkers in Stroke: A Comprehensive Review. Asian Journal of Pharmacy and Technology. 2025; 15(4):370-6. doi: 10.52711/2231-5713.2025.00054 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-4-7
REFERENCES:
1. Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected global trends in ischemic stroke incidence, deaths and disability-adjusted life years from 2020 to 2030. Stroke. 2023; 54(5): 1330-9.
2. Rekatsina M, Paladini A, Piroli A, Zis P, Pergolizzi JV, Varrassi G. Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: a narrative review. Advances in Therapy. 2020; 37(1): 113-39.
3. Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A. Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke. Circulation Research. 2022; 130(8): 1167-86.
4. Przykaza Ł. Understanding the connection between common stroke comorbidities, their associated inflammation, and the course of the cerebral ischemia/reperfusion cascade. Frontiers in Immunology. 2021; 12: 782569.
5. Gaba M, Gaba P, Singh S, Dhingra N. Inhibition of LFA-1/ICAM-1 interaction: A therapeutic strategy for surmounting inflammation. Asian Journal of Pharmaceutical Research. 2015; 5(1): 37-47.
6. Patel JC, Shukla M, Shukla M. Cellular and Molecular Interactions in CNS Injury: The Role of Immune Cells and Inflammatory Responses in Damage and Repair. Cells. 2025;14(12):918.
7. Montellano FA, Ungethuem K, Ramiro L, Nacu A, Hellwig S, Fluri F, et al. Role of blood-based biomarkers in ischemic stroke prognosis: a systematic review. Stroke. 2021; 52(2): 543-51.
8. Mahapatra DK, Shivhare RS, Kumar P. Murrayanine-chalcone transformed into novel pyrimidine compounds demonstrated promising anti-inflammatory activity. Asian Journal of Pharmaceutical Research. 2018; 8(1): 6-10.
9. Tirandi A, Sgura C, Carbone F, Montecucco F, Liberale L. Inflammatory biomarkers of ischemic stroke. Internal and Emergency Medicine. 2023; 18(3): 723-32.
10. Ye Z, Hu T, Wang J, Xiao R, Liao X, Liu M, et al. Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2022; 9: 933913.
11. Dong R, Yi N, Jiang D. Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules. Talanta. 2024; 270: 125529.
12. Dagonnier M, Donnan GA, Davis SM, Dewey HM, Howells DW. Acute stroke biomarkers: are we there yet? Frontiers in neurology. 2021; 12: 619721.
13. di Biase L, Bonura A, Pecoraro PM, Carbone SP, Di Lazzaro V. Unlocking the potential of stroke blood biomarkers: early diagnosis, ischemic vs. haemorrhagic differentiation and haemorrhagic transformation risk: a comprehensive review. International Journal of Molecular Sciences. 2023; 24(14): 11545.
14. Iordache MP, Buliman A, Costea-Firan C, Gligore TCI, Cazacu IS, Stoian M, et al. Immunological and Inflammatory Biomarkers in the Prognosis and Prevention of Ischemic Stroke: A Review of a Decade of Advancement. 2025.
15. Lombardozzi G, Castelli V, Giorgi C, Cimini A, d’Angelo M. Neuroinflammation strokes the brain: a double-edged sword in ischemic stroke. Neural Regeneration Research. 2025: 10. 4103.
16. Song K, Li Y, Zhang H, An N, Wei Y, Wang L, et al. Oxidative stress‐mediated blood‐brain barrier (BBB) disruption in neurological diseases. Oxidative medicine and cellular longevity. 2020; 2020(1): 4356386.
17. Lalitha P, Sachithanandam V, Swarnakumar N, Sridhar R. Review on Anti-inflammatory Properties of Mangrove plants. Asian Journal of Pharmaceutical Research. 2019; 9(4): 273-88.
18. Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion injuries: from pathophysiology to therapeutic strategies. International Journal of Molecular Sciences. 2021; 23(1): 14.
19. Surana KR, Parkhe AG, Ahire ED, Pawar AR, Khairnar S, Mahajan SK, et al. Current therapeutic targets for neuropathic pain. Asian Journal of Pharmaceutical Research. 2022; 12(1): 96-104.
20. Pawluk H, Woźniak A, Grześk G, Kołodziejska R, Kozakiewicz M, Kopkowska E, et al. The role of selected pro-inflammatory cytokines in pathogenesis of ischemic stroke. Clinical Interventions in Aging. 2020: 469-84.
21. Coveney S, Murphy S, Belton O, Cassidy T, Crowe M, Dolan E, et al. Inflammatory cytokines, high-sensitivity C-reactive protein, and risk of one-year vascular events, death, and poor functional outcome after stroke and transient ischemic attack. International Journal of Stroke. 2022; 17(2): 163-71.
22. Leasure AC, Kuohn LR, Vanent KN, Bevers MB, Kimberly WT, Steiner T, et al. Association of serum IL-6 (Interleukin 6) with functional outcome after intracerebral hemorrhage. Stroke. 2021; 52(5): 1733-40.
23. Lakshmi PM, Archana J. Animal Models of Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease. Asian Journal of Pharmaceutical Research. 2025; 15(1): 51-9.
24. Çorbacıoğlu ŞK, Aksel G. Receiver operating characteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. Turkish Journal of Emergency Medicine. 2023; 23(4): 195-8.
25. Sandvig HV, Aam S, Alme KN, Askim T, Beyer MK, Ellekjær H, et al. Plasma inflammatory biomarkers are associated with poststroke cognitive impairment: the Nor-COAST study. Stroke. 2023; 54(5): 1303-11.
26. Ciancarelli I, Morone G, Iosa M, Cerasa A, Calabrò RS, Iolascon G, et al. Influence of oxidative stress and inflammation on nutritional status and neural plasticity: new perspectives on post-stroke neurorehabilitative outcome. Nutrients. 2022; 15(1):108.
27. Alabdali MM, Alrasheed AS, Alghirash FA, Almaqboul TM, Alhashim A, Aljaafari DT, et al. Stress Hyperglycemia as a Prognostic Indicator of the Clinical Outcomes in Patients with Stroke: A Comprehensive Literature Review. Biomedicines. 2025; 13(8): 1834.
28. Porro C, Cianciulli A, Panaro MA. The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules. 2020; 10(7): 1017.
29. Westendorp WF, Dames C, Nederkoorn PJ, Meisel A. Immunodepression, infections, and functional outcome in ischemic stroke. Stroke. 2022; 53(5): 1438-48.
30. Singh V, Kaur R, Kumari P, Pasricha C, Singh R. ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clinica Chimica Acta. 2023; 548: 117487.
31. Wang L, Chen Y, Feng D, Wang X. Serum ICAM‐1 as a predictor of prognosis in patients with acute ischemic stroke. BioMed research International. 2021; 2021(1): 5539304.
32. Yang J, Ran M, Li H, Lin Y, Ma K, Yang Y, et al. new insight into neurological degeneration: Inflammatory cytokines and blood–brain barrier. Frontiers in Molecular Neuroscience. 2022; 15: 1013933.
33. Zhou F, Zhang F, Zarnitsyna VI, Doudy L, Yuan Z, Li K, et al. The kinetics of E-selectin-and P-selectin-induced intermediate activation of integrin αLβ2 on neutrophils. Journal of Cell Science. 2021; 134(18): jcs258046.
34. Purdy M, Obi A, Myers D, Wakefield T. P‐and E‐selectin in venous thrombosis and non‐venous pathologies. Journal of Thrombosis and Haemostasis. 2022; 20(5): 1056-66.
35. Suvarna P, Kumar R, Shetty P, VB NS. Development and in vitro evaluation of fast dissolving tablets of tapentadol. Asian Journal of Pharmaceutical Research. 2016; 6(1).
36. Chen L, Wang M, Yang C, Wang Y, Hou B. The role of high-sensitivity C-reactive protein serum levels in the prognosis for patients with stroke: a meta-analysis. Frontiers in Neurology. 2023; 14: 1199814.
37. Wang H, Tian X, Liao Z, Yue X, Sun L, Li X, et al. Inflammatory biomarkers may be associated with poor outcomes after mechanical thrombectomy. Thrombosis Journal. 2024; 22(1):58.
38. Shah RS, Shah RR, Nitalikar MM, Magdum CS. Microspheres by spray drying: An approach to enhance solubility of Bicalutamide. Asian Journal of Pharmaceutical Research. 2017; 7(3): 183-8.
39. Schweizer J, Bustamante A, Lapierre-Fétaud V, Faura J, Scherrer N, Azurmendi Gil L, et al. SAA (Serum Amyloid A) A Novel Predictor of Stroke-Associated Infections. Stroke. 2020; 51(12): 3523-30.
40. Sarecka-Hujar B, Kopyta I. Risk factors for recurrent arterial ischemic stroke in children and young adults. Advances in Surgical and Medical Specialties. 2023: 229-57.
41. Islam MM, Satici MO, Eroglu SE. Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turkish Journal of Emergency Medicine. 2024; 24(1): 8-19.
42. Hasse IM, Grosse GM, Schuppner R, Van Gemmeren T, Gabriel MM, Weissenborn K, et al. Circulating inflammatory biomarkers in early prediction of stroke-associated infections. International Journal of Molecular Sciences. 2022; 23(22): 13747.
43. Montlha MP. Association Between Cytokine Profile and Disease Severity in Children Infected with Respiratory Syncytial Virus Causing Lower Respiratory Tract Infection: University of the Witwatersrand, Johannesburg (South Africa); 2018.
44. Gadhavi DN, Ghantiya UV, Gondaliya TK. Correlation of Inflammatory Biomarkers (IL-6, CRP, and TNF-α) With Severity and Outcomes in Patients with ST-Elevation Myocardial Infarction (STEMI): A Prospective Cohort Study. Journal of Heart Valve Disease. 2025; 30: 15-9.
45. Bitencourt ACS, Timóteo RP, Bazan R, Silva MV, da Silveira Filho LG, Ratkevicius CMA, et al. Association of proinflammatory cytokine levels with stroke severity, infarct size, and muscle strength in the acute phase of stroke. Journal of Stroke and Cerebrovascular Diseases. 2022; 31(1): 106187.
46. Haydinger CD, Ashander LM, Tan ACR, Smith JR. Intercellular adhesion molecule 1: more than a leukocyte adhesion molecule. Biology. 2023; 12(5): 743.
47. Powanda MC, Moyer ED. A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury. Inflammopharmacology. 2021; 29(3): 897-901.
48. Shi R, Tian Y, Tian J, Liu Q, Zhang J, Zhang Z, et al. Association between the systemic immunity-inflammation index and stroke: a population-based study from NHANES (2015–2020). Scientific Reports. 2025; 15(1): 381.
49. Hardy-Sosa A, León-Arcia K, Llibre-Guerra JJ, Berlanga-Acosta J, Baez SdlC, Guillen-Nieto G, et al. Diagnostic accuracy of blood-based biomarker panels: a systematic review. Frontiers in Aging Neuroscience. 2022; 14: 683689.
50. Siddiqi AZ, Young A, Wadhwa A. Diagnosis and Management of Acute Ischemic Stroke: Intech Open; 2022.
51. Zarei H, Dizaji SR, Toloui A, Yousefifard M, Esmaeili A. Diagnostic and prognostic values of S100B versus Neuron Specific Enolase for Traumatic Brain Injury; a systematic review and Meta-analysis. Archives of Academic Emergency Medicine. 2024; 12(1): e29.
52. Liu X, Zhang T, Yang L, Chen G, Ding P, Yu D, et al. National Institute of Health Stroke Scale Score Mediated the Relationship between Systemic Inflammatory Response Index, High-Sensitivity C-Reactive Protein, and Functional Prognosis of Acute Ischemic Stroke: A Prospective Cross-Sectional Study. Heart and Mind. 2025; 9(3): 174-84.
53. Sandvig HV. The Impact of Systemic Inflammation on Cognitive Function Among Survivors of Ischemic Stroke. 2024.
54. Hovland A, Retterstøl K, Mollnes TE, Halvorsen B, Aukrust P, Lappegård KT. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential? Scandinavian Cardiovascular Journal. 2020; 54(5): 274-9.
55. Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals. 2022; 15(2): 151.
56. Zhang S, Wang D, Li L. Recombinant tissue-type plasminogen activator (rt-PA) effectively restores neurological function and improves prognosis in acute ischemic stroke. American Journal of Translational Research. 2023; 15(5): 3460.
57. Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022; 185(15): 2789-805.
58. Xu H, Wang B, Li A, Wen J, Su H, Qin D. Mesenchymal stem cells-based cell-free therapy targeting neuroinflammation. Aging and Disease. 2024; 15(3): 965.
59. McCabe J, O’reilly E, Coveney S, Collins R, Healy L, McManus J, et al. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: systematic review and meta-analysis. European Stroke Journal. 2021; 6(1): 62-71.
60. Janigro D, Bailey DM, Lehmann S, Badaut J, O'Flynn R, Hirtz C, et al. Peripheral blood and salivary biomarkers of blood–brain barrier permeability and neuronal damage: clinical and applied concepts. Frontiers in Neurology. 2021; 11: 577312.
61. Cassioli g. Decoding the Transcriptome: Gene Expression Profiles in Acute Ischemic Stroke Patients. 2024.
62. Rischke S, Hahnefeld L, Burla B, Behrens F, Gurke R, Garrett TJ. Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects. Journal of Mass Spectrometry and Advances in the Clinical Lab. 2023; 28: 47-55.
63. Zhang J, Liu D, Xiang J, Yang M. Combining glial fibrillary acidic protein and neurofilament light chain for the diagnosis of major depressive disorder. Analytical Chemistry. 2024; 96(4): 1693-9.
64. Abedi V, Avula V, Chaudhary D, Shahjouei S, Khan A, Griessenauer CJ, et al. Prediction of long-term stroke recurrence using machine learning models. Journal of Clinical Medicine. 2021; 10(6): 1286.
65. Liang Y, Chen J, Chen Y, Tong Y, Li L, Xu Y, et al. Advances in the detection of biomarkers for ischemic stroke. Frontiers in Neurology. 2025; 16: 1488726.
66. Chaturvedi S, De Marchis GM. Inflammatory biomarkers and stroke subtype: an important new frontier. Lippincott Williams and Wilkins Hagerstown, MD; 2024. p. e208098.
67. Correia M, Silva I, Gabriel D, Simrén J, Carneiro A, Ribeiro S, et al. Early plasma biomarker dynamic profiles are associated with acute ischemic stroke outcomes. European Journal of Neurology. 2022; 29(6): 1630-42.
68. Chen Y, Li X, Zhang J, Peng J, Huang F, Bao J, et al. Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions. Frontiers in Immunology. 2025; 16: 1616231.
69. Zahoor I, Mir S, Giri S. Profiling blood-based neural biomarkers and cytokines in experimental autoimmune encephalomyelitis model of multiple sclerosis using single-molecule array technology. International Journal of Molecular Sciences. 2025; 26(7):3258.
70. Wang K, Shi Q, Sun C, Liu W, Yau V, Xu C, et al. A machine learning model for visualization and dynamic clinical prediction of stroke recurrence in acute ischemic stroke patients: A real-world retrospective study. Frontiers in Neuroscience. 2023; 17: 1130831.